Beijing Yabao Biological Pharmaceutical

Beijing Yabao Biological Pharmaceutical is a key subsidiary of the Yabao Pharmaceutical Group, a leading Chinese pharmaceutical company listed on the Shanghai Stock Exchange. The company specializes in the research, development, and manufacturing of innovative drugs and high-tech formulations, with a strong focus on therapeutic areas such as neurology, metabolic diseases, and critical care. Its advanced pipeline features promising candidates like SY-007, a neuroprotective peptide for ischemic stroke, and SY-004, a novel glucokinase activator for type 2 diabetes. Operating from the Beijing Economic-Technological Development Area, the company maintains cGMP-certified facilities that support the production of complex drug delivery systems, including sustained-release and transdermal products. Through strategic global partnerships and a commitment to pediatric health, Beijing Yabao continues to expand its footprint in both the domestic and international biopharmaceutical markets.